Related Experiment Video
Updated: Oct 9, 2026

Basophil Activation Test for Allergy Diagnosis
Published on: May 31, 2021
Pharmacist-driven allergy to beta-lactam evaluation in the emergency department
Megan R Passalacqua1, Edward M Stoll2, Lindsay K Hoefling3
1VA Indiana Healthcare System, Indianapolis, Indiana; Purdue University College of Pharmacy, Department of Pharmacy Practice, West Lafayette, Indiana.
Background:
Penicillin (PCN) is the most common drug allergy in medical records and have been linked to suboptimal antibiotic regimens and negative externalities.
Objective:
To evaluate the successful de-labeling of PCN allergies following the implementation of a pharmacist-driven PCN de-labeling protocol in an emergency department (ED) PRACTICE DESCRIPTION: VA Indiana Healthcare System (VAIHCS) is a tertiary level 1A VAMC that registers about 30,000 ED visits annually.
Practice Innovation:
An Allergy to Beta-Lactam Evaluation (ABLE) VA template is available that guides pharmacists through allergy history and provides recommendations on alternative beta-lactam agents. Although a recent pharmacist-led efforts in ED has been described, literature specifically in the ED remains limited.
Evaluation Methods:
This study included patients who presented to the ED over a six-month period and underwent the ABLE protocol. The primary outcome was the percentage of patients whose PCN allergy was de-labeled. Secondary outcomes included the percentage of patients de-labeled within the ED versus de-labeled at follow-up, percentage of patients presenting to the ED with a PCN allergy compared to the number of patients de-labeled, and the number of patients who received beta-lactam antibiotics immediately following pharmacist assessment.
Results:
From May 15, 2024, to October 31, 2024, 44 patients met inclusion criteria. A total of 64% (28/44) had their PCN allergy de-labeled. Of the 28 patients de-labeled, 75% (21/28) were de-labeled via direct oral amoxicillin challenge, and the remainder were de-labeled based on allergy history review alone. Following de-labeling, 36% (10/28) received a beta-lactam antibiotic during the same ED visit. No adverse reactions were observed. There was a 95% follow-up rate at 72 hours post amoxicillin challenge.
Conclusion:
A pharmacist-led PCN de-labeling protocol in the ED is feasible, safe, and facilitates access to beta-lactam antibiotics for eligible patients, while highlighting practical barriers that must be addressed for broader implementation.
Related Concept Videos
Allergic Reactions: Anaphylaxis
Allergic Reactions
Allergic Drug Reactions
Acute Pyelonephritis II: Diagnostic Studies and Management
Drug Toxicity: Allergic Reactions
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:

